Pre-Open Stock Movers 04/06: (TUFN) (BTAI) (TLRY) Higher; (CANO) (CAR) (JBLU) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
BioXcel Therapeutics (BTAI) PT Raised to $84 at Canaccord Genuity
April 7, 2022 7:56 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $84.00 (from $81.00) while maintaining a Buy rating.
The analyst commented, "Earlier today (4/6), BTAI announced that the FDA approved Igalmi (BXCL501, dexmedetomidine film) for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. We had earlier characterized approval as a... More
BioXcel Therapeutics (BTAI) PT Raised to $76 at Jefferies
April 6, 2022 11:40 AM EDTJefferies analyst Chris Howerton raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $76.00 (from $73.00) while maintaining a Buy rating on FDA Approval of IGALMI Sublingual Film.
The analyst noted the label was broad, pricing is soon, and trade-launch in Q3.
... MoreTilray (TLRY) PT Raised to $8.40 at Cantor Fitzgerald
April 6, 2022 10:41 AM EDTCantor Fitzgerald analyst Pablo Zuanic raised the price target on Tilray (NASDAQ: TLRY) to $8.40 (from $6.90) while maintaining a Neutral rating following results and the recent re-rate higher on U.S. news flow.
The analyst commented, "We think the main takeaway from this... More

